Under the terms of the agreement, TG Therapeutics obtains non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation ® technology and ExPERTâ„¢ platform. In return, ...
Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly grow ...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation ... their professional network, aimed at building an inclusive, diverse community.
Kinaset Therapeutics, a clinical-stage biopharmaceutical company developing inhaled therapeutics to treat serious respiratory diseases, today announced that the United States Food and Drug ...
IVIEW Therapeutics Inc., a clinical-stage biotechnology company dedicated to advancing innovative treatments for ocular diseases, today announced positive topline data from its Phase 1/2 clinical ...
Mr. Northcott brings over 20 years of biopharmaceutical experience building commercial organizations and successfully commercializing novel products, including BTK inhibitor ibrutinib SAN FRANCISCO, ...
Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...
Sands, M.D., Ph.D., president and chief executive officer of Nurix. “John’s experience commercializing the BTK inhibitor ibrutinib as well as his experience building commercial teams ahead of ...
Scientists have progressed from merely provoking an anti-cancer immune response to designing it ...
Sands, M.D., Ph.D., Nurix's President and CEO, expressed confidence in Northcott's ability to steer the commercial strategy given his track record with oncology agents and team-building expertise.